BriaCell Therapeutics Corp.

BCT

CA1079301091

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 03:59:51 2024-04-23 pm EDT			5-day change	1st Jan Change
3.15 ^CAD	+7.14%		+0.64%	-59.62%

Apr. 10	BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+? and Bria-PROS+? Clinical Candidates for Breast and Prostate Cancer	CI
Apr. 09	BriaCell to Showcase Latest Bria-IMT Data in Poster Presentations at 2024 AACR	MT

BriaCell Therapeutics Corp.(TSXV:BCT) dropped from S&P/TSX Venture Composite Index

December 31, 2021 at 12:00 am EST

Latest news about BriaCell Therapeutics Corp.

BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+? and Bria-PROS+? Clinical Candidates for Breast and Prostate Cancer	Apr. 10	CI
BriaCell to Showcase Latest Bria-IMT Data in Poster Presentations at 2024 AACR	Apr. 09	MT
BriaCell Therapeutics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	Mar. 18	CI
BriaCell to Present Clinical Data in CNS Metastasis and Antibody-Drug Conjugate Resistant Breast Cancer at AACR Conference	Mar. 06	MT
BriaCell Announces Strong Clinical Data in Breast Cancer Patients	Feb. 07	MT
BriaCell Therapeutics Corp. Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case	Feb. 07	CI
Toronto Stocks Rally; Precision Drilling Rises on 4Q Profit Growth	Feb. 06	DJ
Briacell Therapeutics Corp. Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates Gmp Manufacturing	Feb. 06	CI
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with "Eye-Bulging" Metastatic Breast Cancer	Jan. 04	MT
BriaCell Has Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients	Dec. 28	MT
BriaCell Brief: Has Reported 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients; Comes After Shares Jumped 18% on Wednesday	Dec. 28	MT
BriaCell Therapeutics Corp. Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients	Dec. 28	CI
BriaCell Therapeutics Corp. Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate Refractory Patient Subset	Dec. 20	CI
BriaCell Therapeutics Corp. Reports Earnings Results for the First Quarter Ended October 31, 2023	Dec. 14	CI
BriaCell Highlights Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at Breast Cancer Symposium	Dec. 06	MT
BriaCell Therapeutics Corp. Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS	Dec. 06	CI
BriaCell Therapeutics Corp. Announces Anew Remarkable Responder in Phase 2 Study of the Bria-IMT Combination Regimen	Nov. 30	CI
BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS? IND	Nov. 03	CI
Top Premarket Gainers	23-10-31	MT
BriaCell Therapeutics Corp. Reports Earnings Results for the Full Year Ended July 31, 2023	23-10-25	CI
BriaCell Forms Medical Advisory Board of Breast Cancer Specialists to Advance Lead Oncology Candidate	23-10-25	MT
BriaCell Therapeutics Corp. Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology Candidate	23-10-25	CI
BriaCell Announces Presentations at 2023 Society for the Immunotherapy of Cancer, San Antonio Breast Cancer, Conferences	23-10-18	MT
BriaCell Collaborates With New York Cancer & Blood Specialists for Late-Stage Study of Bria-IMT in Advanced Breast Cancer	23-10-04	MT
HC Wainwright Adjusts BriaCell Therapeutics' Price Target to $20 From $24.85, Keeps Buy Rating	23-10-03	MT

Chart BriaCell Therapeutics Corp.

Duration

Period

More charts

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Companyâs lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patientâs own cancer fighting cells to attack and destroy breast cancer tumors. The Company is advancing its targeted immunotherapy program by prioritizing a Phase II clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor. The Company is focused on conducting a Phase I/IIa clinical trial of Bria-IMT in a combination study with Incyteâs immune PD-1 inhibitor, retifanlimab, in advanced breast cancer. The Company is also developing Bria-OTS, an off-the-shelf personalized approach to whole cell cancer immunotherapy. The Bria-OTS immunotherapy is based on a patientâs HLA-type. Its pipeline also includes Bria-Pros, Bria-Lung, Bria-Mel and sCD80, which are in development to treat various cancers.

Sector

Biotechnology & Medical Research

Calendar

2024-10-23 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.15

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BRIACELL THERAPEUTICS CORP.	-59.62%	36.82M
VERTEX PHARMACEUTICALS INCORPORATED	-0.49%	105B
REGENERON PHARMACEUTICALS, INC.	+3.31%	97.5B
ARGENX SE	+2.94%	22.19B
BIONTECH SE	-16.16%	21.33B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-41.41%	16.6B
BEIGENE, LTD.	-22.87%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+6.32%	14.09B
SAREPTA THERAPEUTICS, INC.	+21.46%	10.99B

Bio Therapeutic Drugs